Clinical Trials Directory

Trials / Unknown

UnknownNCT03143140

The Effect of Percutaneous Radiofrequency Ablation of Feeding Arterial for Hepatocellular Carcinoma

The Clinical Value of Percutaneous Radiofrequency Ablation of Feeding Arterial for Hepatocellular Carcinoma

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
120 (actual)
Sponsor
Peking University Cancer Hospital & Institute · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

To evaluate a novel technique-ultrasound guided percutaneous abaltion of tumor feeding artery before RFA for liver malignancy.

Detailed description

Hepatocellular carcinoma is one of the most common tumor in clinical practice. In recent years, various local therapies, especially radiofrequency ablation (RFA) has been proved safe and effective.The main limitation of RFA is that its therapeutic impact is significant compromised by blood flow cooling effect, especially in hypervascular HCC. Recent studies showed combined therapy of TACE and RFA can decrease the blood supply of tumor, increase ablated volume and therefore improve the outcome. However, TACE application is limited in patients who cannot tolerate this therapy due to the side effects of repeated TACE, poor liver function or previously legated hepatic artery. The present study is focus on "difficult-to-treat" HCC patients who are neither surgical candidates, nor TACE candidates. The investigators introduce the novel treatment mode that RFA followed ultrasound guided percutaneous ablation of tumur feeding arterial to treat these difficult cases and evaluate the clinical effect.

Conditions

Interventions

TypeNameDescription
OTHERPAFApercutaneous ablation of tumor feeding artery
OTHERtumor ablationablation of tumor area directly

Timeline

Start date
2014-05-22
Primary completion
2018-03-31
Completion
2018-12-01
First posted
2017-05-08
Last updated
2018-10-17

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03143140. Inclusion in this directory is not an endorsement.